VEGFA and glioblastoma: Bevacizumab, an anti-angiogenic monoclonal antibody targeting vascular endothelial growth factor A (VEGFA), now often used as a first-line agent for recurrent GBMs, first showed promise for the treatment of recurrent GBM in 2009 and 2010, when a series of studies assessed its use in mono- and combination therapy regimens.